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Chronic Mechanical Circulatory
Support for Inotrope-Dependent Heart
Failure Patients Who Are Not Transplant Candidates
Results of the INTrEPID Trial
Joseph G. Rogers, MD, FACC,* Javed Butler, MD, FACC,† Steven L. Lansman, MD, PHD,‡
Alan Gass, MD, FACC,§ Peer M. Portner, PHD, FACC, Michael K. Pasque, MD,#
Richard N. Pierson III, MD, FACC,** for the INTrEPID Investigators
Durham, North Carolina; Atlanta, Georgia; Valhalla and New York, New York; Palo Alto, California;
St. Louis, Missouri; and Baltimore, Maryland
Objectives This study evaluated the impact of left ventricular assist device (LVAD) support on survival and quality of life in
inotrope-dependent heart failure patients ineligible for cardiac transplantation.
Background The role for LVADs as a bridge to cardiac transplantation has been established, but data supporting their role as
permanent therapy in nontransplant candidates are limited.
Methods The INTrEPID (Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent) trial was a prospec-
tive, nonrandomized clinical trial comparing LVAD with optimal medical therapy (OMT). Fifty-five patients with
New York Heart Association functional class IV symptoms who failed weaning from inotropic support were of-
fered a Novacor LVAD. Eighteen of these patients did not receive an LVAD owing to patient preference (n  14)
or unavailability of the device (n  4) but consented to follow-up and constitute a contemporaneous control
group.
Results The LVAD and OMT patients were well matched for demographic and disease severity measures, except OMT
patients had a lower mean serum sodium (128 mg/dl vs. 134 mg/dl; p  0.001) and a higher mean blood urea
nitrogen concentration (59 vs. 40; p  0.02). The LVAD-treated patients had superior survival rates at 6 months
(46% vs. 22%; p  0.03) and 12 months (27% vs. 11%; p  0.02). Adverse event rates were higher in the OMT
group. Eighty-five percent of the LVAD-treated patients had minimal or no heart failure symptoms. Five LVAD
patients and 1 OMT patient improved sufficiently while on therapy to qualify for cardiac transplantation.
Conclusions Inotrope-dependent heart failure patients who are ineligible for transplantation have a high short-term mortality
rate and derive a significant survival advantage from “destination” mechanical circulatory support. (J Am Coll
Cardiol 2007;50:741–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.063a
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LVAD Therapy for Nontransplant Candidates August 21, 2007:741–7plant, LVAD-treated patients
consistently exhibited improved
end-organ function and nutri-
tional status indicative of interim
physiologic recovery (1–4). Peri-
operative morbidity was demon-
strated to be lower in patients
managed with an LVAD before
transplant compared with those
treated with intravenous inotropic
therapy (5).
The support of several patients
for up to 4 years with their orig-
inal Novacor LVAD (World-
eart, Oakland, California) provided initial evidence that
his mechanical support technology was sufficiently reli-
ble for consideration as “destination therapy” in nontrans-
lant candidates (6,7). The INTrEPID (Investigation of
ontransplant-Eligible Patients Who Are Inotrope Depen-
ent) trial was designed as a feasibility study to evaluate the
ffectiveness of the Novacor LVAD for long-term mechan-
cal circulatory support of patients who were not cardiac
ransplant candidates.
ethods
rial design and conduct. The INTrEPID trial was a
onrandomized, 2-arm clinical trial conducted at 13
enters in the U.S. and Canada with experience implant-
ng the Novacor LVAD as a bridge to transplantation
Appendix). The trial was approved by the U.S. Food and
rug Administration (FDA) as a feasibility study. It was
ypothesized that the LVAD would improve both sur-
ival and quality-of-life measures for patients treated
ith intravenous inotropic therapy for cardiogenic shock,
ompared with an optimal medical therapy (OMT)
reatment strategy.
Qualifying patients meeting the inclusion and exclu-
ion criteria were enrolled in the LVAD or OMT arms of
he trial based primarily upon patient preference or device
vailability (Fig. 1). In practice, recruitment and study
ualification was conducted on hospitalized patients with
ntermittent or continuous invasive hemodynamic assess-
ents confirming the clinical impressions of disease
tatus.
The primary end point of the INTrEPID trial was
ll-cause mortality at 6 months. Secondary end points
ncluded adverse events, functional capacity, and health-
elated quality of life.
The costs of data collection were covered by WorldHeart.
atient care costs were shared by the manufacturer and the
atients’ public or private insurance as a condition of device
vailability. An independent Study Steering Committee
pproved the study design, and a Data and Safety Moni-
oring Board followed the conduct of the trial and adverse
Abbreviations
and Acronyms
CVA  cerebrovascular
accident
LVAD  left ventricular
assist device
NYHA  New York Heart
Association
OMT  optimal medical
therapy
TIA  transient ischemic
attackvents. Patients provided informed consent before enroll- aent, and the Institutional Review Board at each of the
articipating institutions approved the trial.
All of the authors had full access to the data and take
esponsibility for its integrity. All of the authors have read
nd agreed to the manuscript as written.
atients. INCLUSION CRITERIA. Eligible patients were
dults with inotrope-dependent stage D heart failure, an
jection fraction of 25%, and New York Heart Association
NYHA) functional class IV symptoms for3 months before
nrollment and were not candidates for cardiac transplantation
ased upon site-specific transplant program criteria. Patients
ad been treated with maximally tolerated doses of
ngiotensin-converting enzyme inhibitors, beta-blockers,
igoxin, diuretics, and/or other vasodilators. All patients were
eceiving inotropic therapy for clinical and/or hemodynamic
vidence of circulatory failure. Before enrollment, the inotropic
rugs were weaned on 2 separate occasions separated by at least
days. Inability to successfully wean from inotropes was
efined by at least 1 of the following: systemic hypotension,
xacerbation of heart failure symptoms, worsening end-organ
unction, a cardiac index of 2.2 l/min/m2, or a pulmonary
apillary wedge pressure of 20 mm Hg.
XCLUSION CRITERIA. Patients were excluded from the trial
f their body surface area was 1.5 m2 or there was a
ontraindication to chronic anticoagulation. Presence of a
echanical aortic valve constituted an exclusion criterion for
VAD support, because of the thromboembolism risk result-
ng from leaflet immobility (control patients were exempt from
his exclusion criterion). Subjects with a cerebrovascular acci-
ent (CVA) or transient ischemic attack (TIA) within 6
onths before enrollment, a 70% carotid stenosis, or an
lcerated carotid plaque were excluded. Unresolved drug or
Enrollment
Wean from inotropes 
1st attempt 2nd attempt
≥7 day delay 
NYHA class IV symptoms for 3 months
EF ≤25% for 6 months 
Control group met inclusion criteria, but did not receive an LVAD because:
• Patient refused device placement
• Device was not available
• Patient had a mechanical aortic valve
Figure 1 INTrEPID Enrollment Criteria
Enrollment strategy for the INTrEPID trial. Eligible patients had severe left ven-
tricular dysfunction for 6 months, New York Heart Association (NYHA) func-
tional class IV symptoms for 3 months, and were required to fail 2 attempts
at weaning from inotropic support separated by at least 7 days. EF  ejection
fraction; LVAD  left ventricular assist device.lcohol dependency, active systemic infection confirmed by
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August 21, 2007:741–7 LVAD Therapy for Nontransplant Candidatesositive blood culture, a serum creatinine of 5.0 mg/dl, total
ilirubin 5.0 mg/dl, mechanical ventilatory support for 48
at the time of enrollment, or a comorbid medical condition
imiting life expectancy to2 years were also contraindications
o enrollment.
Patients in the OMT group met all study criteria but did
ot receive an LVAD because they chose not to undergo
VAD implantation, a mechanical aortic valve was present,
r there were inadequate identifiable financial resources to
over the cost of device implantation and follow-up.
rocedure and follow-up. The Novacor LVAD is a sur-
ically implanted 1 kg electromagnetically actuated blood
ump capable of outputs up to 10 l/min. A conduit placed
n the left ventricular apex diverts blood into the pump, and
he pump returns blood to the ascending aorta. A driveline
unneled across the abdominal wall is connected to a
earable controller (0.6 kg) that regulates and monitors
ump function and a pair of portable batteries (2.7 kg) that
rovide uninterrupted power for 6 h.
The LVAD recipients were managed with an antithrom-
otic regimen that included early postoperative heparin
postoperative day 2; target partial thromboplastin time
55 s), coumadin to a target international normalized ratio
f 2.5 to 3.5, aspirin 81 to 325 mg/day, and dipyridamole 75
g 3 times/day. Clopidogrel, 75 mg daily, could be used at
he investigator’s discretion.
Functional capacity was determined using NYHA func-
ional class assessment. Minnesota Living With Heart
ailure Questionnaire and SF-36 Health Survey scores were
btained at 1, 3, 6, and 12 months after enrollment and
nnually thereafter.
tatistical analysis. Categoric variables are presented as per-
entages and were analyzed using chi-square tests. Continuous
ariables are presented as means with standard deviation and
ere analyzed using the unpaired Student t test. Adverse
vents were analyzed as time-dependent variables and statisti-
ally compared using Cox F test (8). Survival was analyzed as
discrete end point at 6 and 12 months using the log-rank test.
aplan-Meier survival curves were generated and statistically
nalyzed using the log-rank test. Patients were censored with
espect to subsequent follow-up at the time of transplantation.
or all analyses, a p value of 0.05 was considered to be
tatistically significant. All analyses were conducted using SAS
tatistical software (SAS Institute, Cary, North Carolina).
esults
f the 81 patients screened between March 2000 and May
003, 55 were enrolled in the trial. The presence of
xclusion criteria (n  10) and death before enrollment
n  7) were the primary reasons for nonparticipation.
xacerbation of heart failure symptoms constituted the
rimary reason for inability to wean from inotropic support
n 94% of the OMT and 84% of the LVAD cohorts.
Baseline characteristics of the patients are shown in Table 1.
oth OMT and LVAD patients had systemic hypotension wmean arterial pressure: OMT: 63  17 mm Hg; LVAD:
4  3 mm Hg; p  0.86), and a severely reduced left
entricular ejection fraction (OMT: 13.2  2.0; LVAD:
4.2 3.8; p 0.47). Left- and right-sided filling pressures
ere elevated despite OMT and positive inotropic drugs.
oth groups had end-organ hypoperfusion as evidenced by
levated liver function tests, elevated blood urea nitrogen
nd creatinine, and hyponatremia. The groups were well
atched with regard to predictors of adverse outcomes in
eart failure, except that OMT patients had lower serum
odium than the LVAD patients (128  8.0 mmol/dl vs.
34  4.3 mmol/dl; p  0.001), and a higher blood urea
itrogen (60  34.0 mg/dl vs. 41  25.9 mg/dl; p  0.02).
Patients treated with an LVAD had superior survival
ates at 6 months (46% vs. 22%; p  0.03) and 12 months
27% vs. 11%; p  0.02) compared with patients treated
ith OMT (Fig. 2). The hazard ratio for mortality associ-
ted with LVAD support was 0.46 (95% confidence interval
.25 to 0.85). Causes of death are shown in Table 2. In the
MT group, all of the patients died of cardiovascular
ysfunction (primarily heart failure), whereas stroke (34%)
nd infection (24%) accounted for the majority of deaths in
he LVAD group. A total of 5 patients (13.5%, time from
nrollment 6 to 23 months) in the LVAD group and 1
atient (6%, time from enrollment 16 months) in the OMT
roup became eligible for and received a cardiac transplant.
The rates of nonfatal adverse events are shown in Figure 3.
leeding was more frequently seen in the LVAD group and
aseline Characteristicsf the INTrEPID Population
Table 1 Baseline Characteristicsof the INTrEPID Population
Variable
LVAD
(n  37)
OMT
(n  18) p Value
Age, yrs 60.0 11.2 58.0 9.9 0.40
Female, % 8 28 0.10
BSA, m2 1.96 0.28 1.98 0.18 0.75
Nonischemic, % 43 28 0.38
Prior CABG, % 32 56 0.14
Prior CVA, % 16 11 0.71
ICD, % 46 61 0.39
Albumin, g/dl 3.3 0.5 3.5 0.3 0.25
SGOT, U/l 64 156 62 46 0.73
SGPT, U/l 77.8 182 46.9 46.4 0.55
BUN, mg/dl 40.8 25.9 59.9 34.0 0.02
Creatinine, mg/dl 1.8 0.9 2.1 1.0 0.24
Sodium, mmol/dl 134 4.3 128 8.0 0.001
EF, % 14.2 3.8 13.2 2.0 0.47
MAP, mm Hg 64.4 3.8 63.1 17.0 0.86
RA, mm Hg 13.1 7.5 16.2 6.5 0.15
PAS, mm Hg 55.5 13.5 58.2 13.3 0.53
PCWP, mm Hg 24.7 8.1 29.2 8.0 0.06
PVR, dynes/s/cm5 318.8 199.4 341.1 300.1 0.77
SA  body surface area; BUN  blood urea nitrogen; CABG  coronary artery bypass grafting;
VA  stroke; EF  ejection fraction; ICD  implantable cardiac defibrillator; LVAD  left
entricular assist device; MAP  mean arterial pressure; OMT  optimal medical therapy; PAS 
ulmonary artery systolic pressure; PCWP  pulmonary capillary wedge pressure; PVR  pulmo-
ary vascular resistance; RA  right atrial pressure; SGOT  serum glutamic oxaloacetic trans-
minase; SGPT  serum glutamic pyruvic transaminase.as most common during the perioperative period. Cardio-
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LVAD Therapy for Nontransplant Candidates August 21, 2007:741–7ascular dysfunction and renal dysfunction were more com-
on in the OMT group. There was a strong trend toward
higher stroke rate in LVAD patients (p  0.06). The
nfection rate was similar between groups. When evaluated
s time-dependent variables, the highest risk for an adverse
vent was seen during the first month after implant and
eclined thereafter.
The CVA and TIA rates are shown in Figure 4. Twenty
VAD patients experienced 30 strokes, and 10 patients
xperienced 15 TIAs. Overall, 62% of LVAD patients and
1% of OMT patients experienced a stroke or TIA during
he study. The risk of stroke was highest during the first
onth after device implant and subsequently decreased over
ime to a rate of 0.1 events/patient-month. The TIA rate
as low and remained constant throughout the trial.
Patients in the OMT group experienced no improvement
n NYHA functional class (Fig. 5). In contrast, 85% of the
VAD patients had either no symptoms or minimal heart
ailure symptoms at the last assessment. Minnesota Living
ith Heart Failure Questionnaire scores and SF-36 Health
urvey physical and mental functioning scores improved
0
0.2
0.4
0.6
0.8
1
0 6 12 18 24 30 36 42
Months in Trial
S
u
rv
iv
al
p = 0.011 (log-rank test)
Error bars ± 1 standard error
Hazard Ratio 0.461
95% CI (0.249, 0.853)
LVAD
OMT P=0.011(log-rank test)
No. at risk
LVAD
OMT
37 17 8 6 4 4 3 3
18 4 2 0
Time OMT
Hazard Ratio
(95% CI) p-value
6 Mo
12 Mo
22%
11%
46%
27%
LVAD
0.47 (0.23-0.93)
0.48 (0.25-0.91)
0.03
0.02
Survival
Figure 2 Survival Analysis for LVAD and OMT Groups
Survival at 6 months and 12 months demonstrates an approximate 50% reduc-
tion in the risk of death at these time points. Kaplan-Meier survival curves are
also shown. The X represents censoring at the time of transplantation. CI 
confidence interval; LVAD  left ventricular assist device; OMT  optimal medi-
cal therapy.
ause of Death
Table 2 Cause of Death
LVAD
(n  29/37)
OMT
(n  17/18)
Cardiac dysfunction 5 17
CVA 10 0
Infection 7 0
Respiratory failure 2 0
Arrhythmia 1 0
Bleeding 1 0
Multisystem organ failure 1 0
Nonembolic colon ischemia 1 0
Renal failure 1 0mbbreviations as in Table 1.hroughout the observation period in the LVAD group
data not shown). The small number of OMT patients in
his trial did not permit a meaningful comparison of the
uality-of-life measures.
iscussion
utcomes in the INTrEPID trial highlight several impor-
ant issues for patients with advanced/end-stage heart fail-
re and their caregivers. Medically managed patients who
re dependent upon inotropic therapy to maintain end-
rgan perfusion, reasonable hemodynamics, and modest
esidual congestion had a mortality rate of nearly 90% at 1
ear. In a similar group of patients, LVAD support resulted
n a significant survival advantage associated with functional
nd quality-of-life improvements. This suggests that the
enefits of restoring a relatively normal hemodynamic pro-
le outweigh the surgical risk and subsequent device-related
omplications.
The present OMT patient outcomes and reports from
ther researchers consistently demonstrate that end-stage
eart failure patients who are clinically failing standard
herapies have limited therapeutic options and a poor
rognosis. The 6- and 12-month mortality rates in patients
reated with medical therapy in this trial were 78% and 89%,
espectively. In a similar study population in whom inotropic
herapy was not required for enrollment, the REMATCH
Randomized Evaluation of Mechanical Assistance for the
reatment of Congestive Heart Failure) investigators dem-
nstrated mortality rates of 75% at 1 year and 92% at 2 years
n patients treated with evidence-based pharmacotherapeu-
ic regimens (9). The survival of OMT patients in the
resent report is even less favorable and is similar to the
ershberger et al. (10) series of patients treated with
mbulatory inotropic therapy, who experienced a 90%
0
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Figure 3 Adverse Event Rates
Adverse event rates (events/patient-month of follow-up) are shown for all sta-
tistically significant events, as well as those of clinical interest where signifi-
cant differences were not demonstrated between LVAD and OMT. CVA 
cerebrovascular accident (stroke); other abbreviations as in Figure 2.ortality rate at 12 months.
T
h
n
t
c
b
o
l
c
l
q
f
t
a
p
c
a
f
w
r
m
c
d
f
R
b
t
b
p
m
o
o
m
m
t
c
I
p
T
i
t
t
a
(
t
d
t
d
f
R
e
745JACC Vol. 50, No. 8, 2007 Rogers et al.
August 21, 2007:741–7 LVAD Therapy for Nontransplant CandidatesTo date, only the REMATCH trial, which used the
horatec HeartMate XVE LVAD (Pleasanton, California),
as examined the role of mechanical circulatory support in
ontransplant candidates (9). The results of the INTrEPID
rial reinforce the REMATCH data by demonstrating
linically significant short- and intermediate-term survival
enefits in LVAD-treated patients associated with quality-
f-life improvements. These trials also illustrate the chal-
enges of obtaining good results with LVAD therapy in this
ritically ill patient population.
The nonrandomized INTrEPID study design was se-
ected as the best compromise to manage the ethical
uandary faced by inotrope-dependent patients excluded
rom transplantation. Multiple nonrandomized bridge-to-
ransplant analyses have demonstrated superior morbidity
nd mortality outcomes in LVAD-treated patients com-
ared with medically treated patients. Therefore, the pre-
ondition of equipoise between two treatment strategies for
randomized clinical trial was contentious within the heart
CVA
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Figure 4 Rates of Adverse Neurologic Events
The risk of stroke was greatest during the first month following device implantation
the OMT group had neurologic events (1 CVA, 1 TIA). TIA  transient ischemic atta
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LVAD (n=22)OMT (n=11)
Figure 5 NYHA Functional Class
At the last measurement of functional class, 85% of LVAD recipients were
asymptomatic or had minimal heart failure symptoms. Abbreviations as in
Figures 1 and 2.tailure community. At the time that the INTrEPID trial
as designed, REMATCH enrollment was slow, partially
elated to patient reluctance to accept assignment to the
edical therapy arm. In response, the INTrEPID steering
ommittee and the FDA reviewers did not feel that ran-
omization of patients to medical therapy represented a
easible study design. Supported by the highly concordant
EMATCH results, we conclude that it would no longer
e ethical or appropriate to randomize patients to medical
herapy in an LVAD trial for inotrope-dependent patients,
ased on the significant survival advantage experienced by
atients who received an LVAD (11).
The survival rate for both the LVAD and OMT treat-
ent groups in the INTrEPID trial was lower than that
bserved in the REMATCH trial, highlighting the severity
f illness of patients enrolled in this trial. Although the
ajority of baseline characteristics that predict heart failure
ortality were similar between the LVAD arms of both
rials, statistically robust comparisons are not feasible, be-
ause of fundamental differences in the patient populations.
t is clear that study selection criteria in both trials identified
atients with a very high 30-day operative mortality risk.
he REMATCH investigators reported superior outcomes
n LVAD recipients enrolled during the second half of the
rial, suggesting that refinement of patient selection, surgical
echnique, and postoperative management may have favor-
bly influenced the trial outcomes for the LVAD patients
12). The small size and short duration of the INTrEPID
rial did not permit a similar analysis. Finally, intrinsic
ifferences in pump design may have influenced survival in
he LVAD-treated patients in the INTrEPID trial.
An important concern about the use of mechanical
evices for the long-term definitive treatment of heart
ailure is the risk of adverse events. The INTrEPID and
EMATCH trials demonstrated that LVAD recipients are
xposed to an incremental risk of neurologic events, infec-
TIA
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LVAD Therapy for Nontransplant Candidates August 21, 2007:741–7reated patients were at greater risk for heart and renal
ailure as well as increased early mortality. In contrast to the
EMATCH trial, the risk of significant device malfunction
n the INTrEPID trial was very low. Only 1 INTrEPID
atient experienced failure of an implanted component
fracture of a pump-drive decoupling spring), which did not
esult in an appreciable change in pump performance. No
ump replacements were required during the conduct of this
rial, and there was no mortality attributable to LVAD
alfunction.
Neurologic adverse events continue to represent a signif-
cant cause of morbidity and mortality in LVAD trials (13).
e believe that the major contributor to stroke risk in the
NTrEPID trial was the inflow conduit vascular graft
aterial previously used in the Novacor LVAD. Examina-
ion of both DeBakey and Vascutek inflow conduits recov-
red from devices used in this trial revealed a lining of friable
annus. We postulate that a substantial proportion of the
eurologic events were particuloembolic, caused by material
riginating on the pannus (14). Since completion of the
NTrEPID trial, the Novacor LVAD inflow conduit ma-
erial has been changed to ePTFE, eliminating pannus
ormation. This modification reduced the stroke rate to
.3% in a series of 57 LVAD recipients supported for a
umulative duration of 53.5 years (15).
Five LVAD recipients (13.3%) with transplant contrain-
ications at enrollment successfully underwent transplanta-
ion after a period of support. Bridging patients to trans-
lant candidacy is increasingly recognized as a viable and
ppropriate management strategy based upon physiologic
mprovements commonly observed after a period of LVAD
upport. Young et al. (16) recently reported a retrospective
nalysis of the original Novacor bridge-to-transplant clinical
rial, and found that 37% of LVAD-treated patients had1
ontraindication to transplantation that would have pre-
luded listing by at least 1 of 10 high-volume U.S. trans-
lant centers. These LVAD-treated patients had a 6-fold
mprovement in survival compared with medically treated
atients and a similar survival to patients without transplant
ontraindications. The International Society for Heart and
ung Transplantation Mechanical Circulatory Support
egistry has reported that 11% of patients who had an
VAD inserted as destination therapy have subsequently
ndergone transplantation (17). The present findings sup-
ort the long-term use of LVADs as a viable option for
elected patients with medical, social, or financial obstacles
o transplant candidacy at the time of transplant evaluation.
tudy limitations. The INTrEPID trial is the second
tudy to demonstrate the value of mechanical circulatory
upport in nontransplant candidates with advanced heart
ailure. Because the trial design was nonrandomized, it is
ossible that institutional or investigator bias contributed
o patients’ decisions to continue medical therapy rather
han receive a LVAD. Although patient characteristics of
he study populations were similar, there were differencesn baseline BUN and serum sodium. We cannot exclude
he possibility that these differences biased study findings
gainst medical therapy in ways that are difficult to
easure.
On the other hand, stringent enrollment criteria identi-
ed a population of patients with extremely poor prognosis
nd end-organ dysfunction that may have limited device
fficacy. These enrollment criteria define critically ill and
nstable patients with short- and intermediate-term mor-
idity and mortality (both medical and surgical) as high as
hat of any reported heart failure population. We speculate
hat the benefits of mechanical circulatory support may be
ore robust in a patient population with less advanced cardiac
isease and/or end-organ failure, because such patients may
ot experience the high early mortality (24% at 1 month; 36%
t 3 months) associated with LVAD insertion.
onclusions
his report demonstrates the feasibility of destination
VAD support using the Novacor device, thus accomplish-
ng the primary goal of the INTrEPID trial.
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